HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term results with lanreotide in patients with recurrent gastrointestinal angiodysplasias bleeding or obscure gastrointestinal bleeding. Benefits in efficacy and procedures consumption.

AbstractBACKGROUND:
Gastrointestinal angiodysplasias (GIAD) bleeding and obscure gastrointestinal bleeding (OGIB) are increasing health problems. Somatostatin analogues have been proposed as rescue therapy, but data for lanreotide are scarce.
OBJECTIVE:
To determine the efficacy, safety and resource saving of long-acting lanreotide for GIAD and OGIB.
METHODS:
Retrospective study including adults with GIAD bleeding or OGIB and lanreotide treatment for at least 6 consecutive months. Demographics, comorbidities and treatments were collected. Anaemia and health resource consumption were analysed and compared between the year before and three years after starting lanreotide. Complete response was defined as a lack of new blood transfusion or endovenous iron dose need.
RESULTS:
Twenty-seven patients (mean age 76.8 years) were included, 63% taking anticoagulants/antiplatelets. The bleeding was attributable to angiodysplasia in 85.2%, of whom half had multi-site lesions. Lanreotide was administered for a median of 27.1 months. During follow-up of up to 3 years (mean 32.5 months), 18.5% of patients achieved complete response and around 60% a 50% reduction of health resource consumption. Haemoglobin values improved (p = .007), while admission time, blood/iron infusions, and the number of endoscopies decreased significantly (p<.05) at least up to the second year. There were no relevant side effects during the follow-up period.
CONCLUSION:
Long-term treatment with lanreotide significantly improves anaemia and decreases health resource consumption in patients with recurrent GIAD bleeding or OGIB.
AuthorsSantiago Frago, Javier Alcedo, Edgar Martín Pena-Galo, María Lázaro, Leticia Ollero, Natalia de la Llama
JournalScandinavian journal of gastroenterology (Scand J Gastroenterol) Vol. 53 Issue 12 Pg. 1496-1502 (Dec 2018) ISSN: 1502-7708 [Electronic] England
PMID30621520 (Publication Type: Journal Article)
Chemical References
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
Topics
  • Aged
  • Aged, 80 and over
  • Anemia (etiology, therapy)
  • Angiodysplasia (complications)
  • Blood Transfusion
  • Capsule Endoscopy
  • Chronic Disease
  • Female
  • Gastrointestinal Hemorrhage (therapy)
  • Humans
  • Logistic Models
  • Male
  • Peptides, Cyclic (administration & dosage)
  • Recurrence
  • Retrospective Studies
  • Somatostatin (administration & dosage, analogs & derivatives)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: